Biliary Tract Cancer
Conditions
Keywords
second line
Brief summary
Phase II Study of Refametinib, a MEK inhibitor, as second-line treatment in advanced biliary tract adenocarcinoma
Detailed description
Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule. Self-administration of refametinib tablets will take place on an outpatient basis. Patients experiencing dose-limiting toxicity attributed to study medication should have at least 1-week treatment breaks inserted into the continuous daily dosing period as needed and/or may be interrupted or reduced depending on individual tolerability.
Interventions
DRUGrefametinib
Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
Sponsors
Samsung Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. age ≥ 18 2. histologically or cytologically confirmed adenocarcinoma of biliary tract 3. unresectable or metastatic 4. ECOG performance status of 0\ 2 5. measurable lesion per RECIST 1.1 criteria 6. adequate marrow, hepatic, renal functions 7. normal range of cardiac function confirmed by echocardiogram within 1 year (LVEF ≥50) 8. Child-Pugh Class A in case of liver cirrhosis 9. One prior treatment of cytotoxic chemotherapy (including adjuvant treatment within 12 months) 10. Resolution of all acute toxic effects of any prior therapy to Common Toxicity Criteria for Adverse Events (CTCAE 4.03) ≤ grade 1. 11. provision of a signed written informed consent
Exclusion criteria
1. History of cardiac disease 2. Ongoing infection \> Grade 2 according to NCI-CTCAE version 4.03. Hepatitis B is allowed if no active replication (defined as abnormal ALT \>2xULN associated with HBV DNA \>20,000 IU/mL) is present 3. Severe co-morbid illness and/or active infections including active hepatitis C and human immunodeficiency virus (HIV) infection 4. History of interstitial lung disease (ILD). 5. Any cancer curatively treated \< 3 years prior to study entry, except cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Staging: Ta, Tis and T1). 6. Renal failure requiring hemo- or peritoneal dialysis. 7. Clinically significant GI bleeding (CTCAE 4.03 grade 3 or higher) within 30 days prior to start of screening 8. Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks) within 6 months prior to start of screening. 9. History of organ allograft, cornea transplantation will be allowed 10. Active CNS metastases not controllable with radiotherapy or corticosteroids 11. Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR. 12. Known history of hypersensitivity to study drugs 13. Any condition that was unstable or which could jeopardize the safety of the patient and his/her compliance in the study 14. Non-healing wound, ulcer, or bone fracture. 15. Patients with seizure disorder requiring medication. 16. Use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4 should be stopped 2 weeks before start of screening (see Appendix 1). 17. Acute steroid therapy or taper for any purpose (chronic steroid therapy is acceptable provided that the dose is stable for 1 month before start of screening and thereafter). 18. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results. 19. Pregnant or lactating women. Women of childbearing potential not employing adequate contraception. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to start of study treatment and a negative result must be documented before first dose of study drug.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response rate | 12months | the rate of complete response and partial response among all evaluable patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| adverse events in each cycle were documented based on CTCAE v 4.03 | 24months | — |
| Duration of response | 12months | median time from response to progression |
| Progression-free survival | 6months | — |
| Exploratory correlative analysis | 15 days | KRAS/PIK3CA mutation testing using BEAMing assay will be planned |
| Overall survival | 12months | — |
Outcome results
None listed